Clinical Trial Update: A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 study evaluating VAK694 in combination with allergen immunotherapy to induce specific immune tolerance in season…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• VAK694

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Seasonal Allergic Rhinitis | Phase 2 | Status: COMPLETED